1-5 of 5
Murphy Hentemann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1

Warren C. Fiskus, Christopher Peter Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Christine Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Surbhi Sharma, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2024) 144 (Supplement 1): 1373.
https://doi.org/10.1182/blood-2024-206374
Published: 2024
Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Warren Fiskus, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill, Christine E. Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Antrix Jain, Anna Malovannaya, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Danielle Hammond, Patrick K. Reville, Jian Wang, Sanam Loghavi, Rwik Sen, Xinjia Ruan, Xiaoping Su, Lauren B. Flores, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2024) 143 (20): 2059–2072.
https://doi.org/10.1182/blood.2023022832
Published: 2024
Includes: Supplemental data
Journal Articles

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari, Amir T. Fathi, Kapil N. Bhalla, Samuel Agresta, Sarah Reilly, Caroline Almon, Murphy Hentemann, Denice Hickman, Dillon Corrigan, Meghan Macaraeg, Jessica Piel, Kim Horrigan, Salah Nabhan, Paul Martin, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 4284.
https://doi.org/10.1182/blood-2023-178090
Published: 2023
Journal Articles

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Branko Cuglievan, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2023) 142 (Supplement 1): 4160.
https://doi.org/10.1182/blood-2023-182575
Published: 2023
Journal Articles

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine E Birdwell, Kaberi Das, John A. Davis, Noor Alhamadani, Kevin Philip, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 8819–8820.
https://doi.org/10.1182/blood-2022-164513
Published: 2022